Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial

Published:2019-03 Issue:3 Volume:7 Page:249-259
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

von Groote-Bidlingmaier Florian,Patientia Ramonde,Sanchez Epifanio,Balanag Vincent,Ticona Eduardo,Segura Patricia,Cadena Elizabeth,Yu Charles,Cirule Andra,Lizarbe Victor,Davidaviciene Edita,Domente Liliana,Variava Ebrahim,Caoili Janice,Danilovits Manfrid,Bielskiene Virgaine,Staples Suzanne,Hittel Norbert,Petersen Carolyn,Wells Charles,Hafkin Jeffrey,Geiter Lawrence J,Gupta Rajesh

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference26 articles.

1. Target regimen profiles for treatment of tuberculosis: a WHO document;Lienhardt;Eur Respir J,2017

2. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients;Diacon;Int J Tuberc Lung Dis,2011

3. Delamanid for multidrug-resistant pulmonary tuberculosis;Gler;N Engl J Med,2012

4. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid;Wells;Eur Respir J,2015

5. Delamanid for extensively drug-resistant tuberculosis;Gupta;NEJM J,2015

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of effectiveness and safety of delamanid-containing regimens using individual patient datasets;The International Journal of Tuberculosis and Lung Disease;2024-09-01

2. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs;Journal of Microbiology, Immunology and Infection;2024-08

3. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug‐Resistant and Extensively Drug‐Resistant Mycobacterium tuberculosis;Journal of Clinical Laboratory Analysis;2024-08

4. Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid;Scientific Reports;2024-07-29

5. Real-life use of delamanid: results from the European post-authorisation safety study;IJTLD OPEN;2024-06-01